Hanmi Pharmaceutical Company Limited

hanmi.co.kr

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

188

Active

13

Phase 3

37

Total enrollment

53,311

Pipeline matrix

Showing 18 of 18 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
HM11260C8
HCP1803-35
RLD2001-14
RLD2001-23
HCP1803-41
HM152753
HM151363
HM152112
HM15912 Active1
Belvarafenib1
Cobimetinib1
pembrolizumab3
HCP13065
BH31201
HM163901
HIP25031
HM173211
HM976621

Next readouts

  • 2026-03-25
  • 2026-06-27
  • 2026-07
  • 2027-01
  • 2027-03
  • 2027-08
  • 2027-10
  • 2027-10-30
  • 2027-11
  • 2027-12

Top conditions

  • Healthy51
  • Hypertension23
  • Diabetes Mellitus8
  • Obesity6
  • Erectile Dysfunction5
  • Non Small Cell Lung Cancer4
  • Hyperlipidemia4
  • Type 2 Diabetes Mellitus4

Frequently asked questions about Hanmi Pharmaceutical Company Limited

How many clinical trials does Hanmi Pharmaceutical Company Limited have on ClinicalTrials.gov?
Hanmi Pharmaceutical Company Limited is listed as the lead sponsor on 188 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
How many of Hanmi Pharmaceutical Company Limited's trials are in Phase 3?
37 of Hanmi Pharmaceutical Company Limited's trials are in Phase 3, spread across 18 active drug programs.
What therapeutic areas does Hanmi Pharmaceutical Company Limited focus on?
Hanmi Pharmaceutical Company Limited's most-studied conditions on ClinicalTrials.gov are Healthy, Hypertension, Diabetes Mellitus, Obesity, Erectile Dysfunction.
When are Hanmi Pharmaceutical Company Limited's next clinical trial readouts?
Hanmi Pharmaceutical Company Limited has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers”, expected around 2026-03-25.